Mind Medicine (MNMD) has released an update.
Mind Medicine (MindMed) Inc. has successfully concluded an End-of-Phase 2 meeting with the FDA, paving the way for Phase 3 trials of their GAD treatment, MM120, set to commence in the latter half of 2024. The company’s MM120, an oral dissolving tablet, demonstrated promising results in Phase 2b trials, showing significant improvements in treating Generalized Anxiety Disorder. With the last FDA approval for a GAD treatment occurring in 2007, MM120’s progression represents a potential breakthrough for GAD sufferers.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
